Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (211-220 of 236) with videos related to

Pageof 24
Sort By:
Journal of Translational Medicine|May 4, 2012
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, et al.
Journal of Translational Medicine|September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Journal of Translational Medicine|September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Medrxiv : the Preprint Server for Health Sciences|August 4, 2020
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Journal for Immunotherapy of Cancer|June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.
Clinical Pharmacology and Therapeutics|November 19, 2020
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 PneumoniaGarth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Cell|October 17, 2017
Tumor and Microenvironment Evolution during Immunotherapy with NivolumabNadeem Riaz, Jonathan J Havel, Vladimir Makarov, et al.
Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
JCO Precision Oncology|November 29, 2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker SummitDaniel F Hayes, Roy S Herbst, Jonathan L Myles, et al.
Pageof 24

Showing results (211-220 of 236) with videos related to

Sort By:
Pageof 24
Journal of Translational Medicine|May 4, 2012
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, et al.
Journal of Translational Medicine|September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Journal of Translational Medicine|September 4, 2022
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, et al.
Medrxiv : the Preprint Server for Health Sciences|August 4, 2020
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Journal for Immunotherapy of Cancer|June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.
Clinical Pharmacology and Therapeutics|November 19, 2020
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 PneumoniaGarth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Cell|October 17, 2017
Tumor and Microenvironment Evolution during Immunotherapy with NivolumabNadeem Riaz, Jonathan J Havel, Vladimir Makarov, et al.
Journal of Cancer Research and Clinical Oncology|December 7, 2016
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanomaThomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
JCO Precision Oncology|November 29, 2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker SummitDaniel F Hayes, Roy S Herbst, Jonathan L Myles, et al.
Pageof 24